SUMMARY A growth chart for girls with Turner syndrome has been prepared using data from four published series of European patients, and evaluated using retrospective data on the heights of girls with Turner syndrome seen at this hospital. The results indicate that calculation of height standard deviation score from this chart allows a reasonable prediction of adult stature in any patient with Turner syndrome. In addition, the results indicate that while oestrogen treatment causes an initial acceleration of growth, it has no significant effect on adult height.
'How tall will she be when she grows up?' is an almost invariable question when the implications of Turner syndrome are explained to parents. To our knowledge, however, there are no growth standards that allow a fairly accurate prediction of adult height in any individual patient with the disorder. We have prepared a growth chart for girls with Turner syndrome, using data given in four previously published series of European patients. The value of this chart in predicting mature height has been evaluated using data on the heights of patients with Turner syndrome seen previously in the outpatient clinics of this hospital.
Method
The growth curve described in this paper has been derived from the mean heights and standard deviations (SD) at different ages in four published series of girls with Turner syndrome; namely 101 patients from Germany described by Pelz et Results Table 1 shows the mean heights and SDs at different ages calculated from the pooled data obtained from the four published series. The average SD for this composite curve is 4.7% of the mean height, which agrees with the average SD in each of the published series (3-7% to 5-1%, mean 4-5%). Figure 1 shows these data as mean (2 SD) plotted on a growth chart for normal girls5 taking the smoothed SD at each age as 4-7% of the mean height. Table 1 also shows the mean (SD) height at different ages for 93 girls with Turner syndrome seen at this hospital. In general, the mean heights are lower than those for the pooled data, although by maturity there was no significant difference. Most of these girls had been treated with oestrogens from the age of 15 years, whereas the data from the published reports were for untreated patients only.
Twenty nine of the 93 girls seen at this hospital had been followed up until the ages of 19 to 24 years, and their growth seemed to be complete. In 12 girls, bone age was assessed at the time of the initial height measurement by the TW2-RUS method,6 and height predictions were made by methods applicable to normal girls.0 The mean error of mature height prediction was then +3-3 cm (that is overprediction) with a range between + 19*7 and -3-3 cm. In contrast, using the growth chart described above, there was a trend to slight underprediction of height by an average of -06 cm. This underprediction was greatest (-3-8 and -1-9 cm) in the two girls with the greatest delay in bone age (5.4 and 4-4 'years' respectively). Although the bone age seemed relevant in these two examples, consideration of bone age delay did not generally improve the predictions in less extreme cases. Table 2 shows the mean SDS on the Turner growth chart for the 29 girls at the time of presentation to outpatients, immediately before and one year after starting oestrogen treatment, and at the final visit to outpatients when aged 19 to 24 years. There was a significant improvement in the mean SDS one year after starting oestrogen (P<001, Student's paired t test) indicating that this treatment had accelerated growth. The mean SDS, however, when last seen in the outpatient clinic had almost returned to the value obtained when the patients were first seen, indicating that treatment had no significant effect on final height.
--
Eight girls, all with mosaic karyotypes, had spontaneous menarche between the ages of 13 and Fig. 2 ).
Discussion
The data used to construct the growth chart described above were obtained from four series of patients attending European centres-the series of Swiss patients described by Brook et al7 has not been included as mean heights without SDs are given in this paper, precluding the incorporation of the data into the composite growth chart.
As there are significant differences in height in different populations, even within northern Europe, the above growth curve will not necessarily represent the actual range of height of girls with Turner syndrome in any given population. For example, the mean heights of the girls seen in London at different ages were generally lower than the combined mean values from the other European centres. The data obtained, however, from the UK indicated quite clearly that in most patients with Turner syndrome there is a close relation between height during the first decade and adult height. It follows that the growth curve described above could have been used to predict final height with a fair degree of accuracy in these patients, simply by calculating the height SDS at presentation and using this SDS to calculate mature height. As would be expected the accuracy of the prediction could have been improved by using the regression equation given above. In girls with extreme delay in skeletal maturation the prediction would probably have been unduly pessimistic; the reverse may be true in girls with advanced skeletal age, but no such patients were present in our small sample.
The relatively poor performance of the multiple regression prediction equations is not surprising as they were developed from groups of normal children who all underwent an adolescent growth spurt, and assume that such a spurt will occur in the test population. Further, it is well recognised that the maturation of the wrist and hand bones in Turner syndrome are discordant and it might be expected that assigned bone age scores would not reflect maturation correctly.
Several authors have reported that there is no significant difference in adult height between patients with 45 X karyotypes and patients with mosaic forms of Turner syndrome, although the mosaic patients were taller in the series reported by Snider.8 In patients seen at this hospital, there was no significant difference in the mean SDS for the 45 X patients and the SDS for those with mosaic karyotypes. Although the growth curve described above was derived from mixed data for patients with 45 X karyotypes and different types of mosaicism, it seemed to be useful in predicting adult height in both these groups of patients.
The growth chart may also be of value in evaluating treatment aimed at increasing final stature in patients with Turner syndrome, for example, the use of anabolic steroids. Our own data do not shed any light on this point as none of the patients who had been followed until growth was complete received such treatment. The results, however, do give further information on the effects of oestrogen treatment on final height in Turner syndrome. This treatment results in a growth spurt, as shown by the change in SDS during the first year of treatment. By the age of 19 years or more, however, most patients had returned to the height centile from which they started, and there was no significant difference between the mean SDS when first seen and that obtained when growth was complete. These observations strongly suggest that treatment with oestrogen at the age of normal puberty had had very little influence on final height.
Appendix
In what follows X, s, and n are used to symbolise the mean height, the standard deviation, and the number of observations respectively. Subscripts i and a are used to indicate the study (i = 1 to 4) and the age group (a= I to 20). Thus xa = mean height for age a combining the data from all four series, whereas kaj would represent any of the four means from the separate studies, but all at age a. S= (=x)2/n}/(n-1) (2) which is identical to:
which by rearrangement gives: x2 = (n-1)s2 + nR2 (4) and 
